the barriers to smoking cessation in swiss methadone and buprenorphine-maintained patients的障碍在瑞士美沙酮和buprenorphine-maintained病人戒烟.pdf

Harm Reduction Journal BioMed Central Research Open Access The barriers to smoking cessation in Swiss methadone and buprenorphine-maintained patients Victoria Wapf, Michael Schaub*, Beat Klaeusler, Lukas Boesch, Rudolf Stohler and Dominique Eich Address: Psychiatric University Hospital Zurich, Research Group on Substance Use Disorders, Selnaustrasse 9, 8002 Zurich, Switzerland Email: Victoria Wapf - mail2victoria@bluewin.ch; Michael Schaub* - mschaub@psychology.ch; Beat Klaeusler - beat.klausler@puk.zh.ch; Lukas Boesch - lukas.boesch@puk.zh.ch; Rudolf Stohler - rudolf.stohler@puk.zh.ch; Dominique Eich - dominique.eich@puk.zh.ch * Corresponding author Published: 18 March 2008 Received: 1 October 2007 Accepted: 18 March 2008 Harm Reduction Journal 2008, 5:10 doi:10.1186/1477-7517-5-10 This article is available from: /content/5/1/10 © 2008 Wapf et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Smoking rates in methadone-maintained patients are almost three times higher than in the general population and remain elevated and stable. Due to the various negative health effects of smoking, nicotine dependence contributes to the high mortality in this patient group. The purpose of the current study was to investigate Swiss methadone and buprenorphin